GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial

GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial

Background: No prognostic biomarker is currently used in clinical management of patients with surgically resected pancreatic cancer other than CA-19-9. In this study, we tested the prognostic value of GATA6 measured with immunohistochemistry and digital assistance. Patients and methods: One hundred...

Full description

Saved in:
Bibliographic Details
Main Authors: R.C. Grant, K. Duan, R. Jackson, W. Greenhalf, E. Costello-Goldring, P. Ghaneh, C. Halloran, D. Palmer, T. Hackert, M. Büchler, S. Hutchinson, S. Ramotar, A. Dodd, J. Wilson, F. Notta, G. O’Kane, J. Knox, J. Neoptolemos, S. Gallinger, S.E. Fischer
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:ESMO Gastrointestinal Oncology
Subjects:
GATA6
pancreatic cancer
biomarkers
digital pathology
Online Access:http://www.sciencedirect.com/science/article/pii/S294981982500007X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S294981982500007X

Similar Items